Hamamatsu, Keita http://orcid.org/0000-0002-0657-2945
Fujimoto, Hiroyuki
Fujita, Naotaka
Murakami, Takaaki
Shiotani, Masaharu
Toyoda, Kentaro
Inagaki, Nobuya
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation
Article History
Received: 10 September 2019
Accepted: 19 November 2019
First Online: 4 December 2019
Competing interests
: N. Inagaki received research funds from Daiichi Sankyo Co., Ltd., and AstraZeneca; received speaker honoraria from Kowa Pharmaceutical Co., Ltd.; received scholarship grant from Kissei Pharmaceutical, Taisho Toyama Pharmaceutical, Sanofi, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Takeda, Japan Tobacco, Kyowa Kirin, Sumitomo Dainippon Pharma, Astellas Pharma, MSD, Eli Lilly Japan, Ono Pharmaceutical, Sanwa Kagaku Kenkyusho, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Novartis Pharma, and Teijin Pharma. K. Toyoda and N. Inagaki have a patent WO2011071083A1 issued to Kyoto University, Arkray, Inc. In addition, M. Shiotani is an employee of Mitsubishi Tanabe Pharma Corporation. All other authors have nothing to disclose.